Nearly half of adults over the age of 65 have some degree of frailty, and over two-thirds have cardiac disease.

Dr Eduard Shantsila discusses the importance of individualised rehabilitation programmes in these patients, to reduce morbidity and mortality, and improve quality of life.

For more on how Springer Medicine can tailor medical education to meet your needs, head to SpringerMedicine.com and register for updates.

Despite many recent advances in its management, type 1 diabetes remains a burden for those living with the condition.

Prof Chantal Mathieu explains the progress being made with disease-modifying therapy for type 1 diabetes and how it has the potential to transform the current treatment landscape.

For more on how Springer Medicine can tailor medical education to meet your needs, head to SpringerMedicine.com and register for updates.

Recent research suggests that the gut microbiome could be an important modulator of response to CAR T-cell therapy in patients with hematologic cancers.

Prof. Marion Subklewe takes us through the latest evidence, highlighting the impact of antibiotics, nutrition, and dietary supplements, and discusses how to devise interventions to improve patient outcomes.

For more on how Springer Medicine can tailor medical education to meet your needs, head to SpringerMedicine.com and register for updates.

About 50% of stroke patients have an unfavorable outcome. Predicting outcome is challenging but is key to understanding how best to treat patients.

Prof. Susanne Wegener discusses her team’s work to develop deep learning models that outperform neurologists when predicting outcome based on imaging data alone or in combination with clinical data.

For more on how Springer Medicine can tailor medical education to meet your needs, head to SpringerMedicine.com and register for updates.

The ADAURA trial has, as of this year, demonstrated an overall survival benefit with the adjuvant use of osimertinib in people with resectable NSCLC.

We take an in-depth look at the study with Dr. Luis Paz-Ares, who outlines the study findings, discusses the clinical implications, and addresses the pertinent questions raised by the trial.

For more on how Springer Medicine can tailor medical education to meet your needs, head to SpringerMedicine.com and register for updates.

New trial data comparing OCT and IVUS as imaging options in PCI has reignited excitement around the potential benefits of OCT in cardiology.

Drs Niels Holm and Lene Andreasen bring us up to speed with the latest evidence, and explore whether we should expect to see this technology in use in our clinics in the future.

For more on how Springer Medicine can tailor medical education to meet your needs, head to SpringerMedicine.com and register for updates.

Next-generation sequencing is a powerful tool that can identify mutations or fusions in a wide range of cancers, enabling physicians to provide targeted therapy to patients and improve outcomes. In this podcast, Professor Andrew Beggs discusses practical aspects of this technique from the clinical viewpoint.

This content is intended only for healthcare providers and was made possible by educational funding provided by Illumina, Inc., and Eli Lilly and Company.

For more on how Springer Medicine can tailor medical education to meet your needs, head to SpringerMedicine.com and register for updates.

STEM-PD, the first in-human safety trial of stem cell therapy for Parkinson’s disease, began this year and marks a huge step forward for this type of treatment.

We talk to Prof. Malin Parmar about why stem cell therapy is such a good option for patients with Parkinson’s disease and get an update on the current status of the trial.

For more on how Springer Medicine can tailor medical education to meet your needs, head to SpringerMedicine.com and register for updates.

Resistant hypertension is a difficult to treat and often misunderstood phenomenon that continues to frustrate cardiologists.

In this episode, Professors Morris Brown and Bryan Williams debate the causes of resistant hypertension and explore novel treatment options.

For more on how Springer Medicine can tailor medical education to meet your needs, head to SpringerMedicine.com and register for updates.

PARP inhibitors are an emerging treatment option for metastatic castration-resistant prostate cancer and the 2023 ASCO Genitourinary Cancers Symposium saw initial analyses and updates from several trials of these agents that help to address some gaps in the current understanding.

In this episode, Dr. Elena Castro takes us through the latest evidence for PARP inhibitors and their combinations in this setting.

For more on how Springer Medicine can tailor medical education to meet your needs, head to SpringerMedicine.com and register for updates.